ID   MARK1_HUMAN             Reviewed;         795 AA.
AC   Q9P0L2; D3DTB0; D3DTB1; Q2HIY1; Q5VTF9; Q5VTG0; Q96SW9; Q9P251;
DT   12-APR-2005, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   10-MAY-2017, entry version 152.
DE   RecName: Full=Serine/threonine-protein kinase MARK1;
DE            EC=2.7.11.1;
DE            EC=2.7.11.26;
DE   AltName: Full=MAP/microtubule affinity-regulating kinase 1;
DE   AltName: Full=PAR1 homolog c;
DE            Short=Par-1c;
DE            Short=Par1c;
GN   Name=MARK1 {ECO:0000312|HGNC:HGNC:6896};
GN   Synonyms=KIAA1477 {ECO:0000312|EMBL:BAA96001.1},
GN   MARK {ECO:0000312|EMBL:AAF72103.1};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), ENZYME REGULATION,
RP   PHOSPHORYLATION AT THR-215, AND MUTAGENESIS OF THR-215.
RX   PubMed=14976552; DOI=10.1038/sj.emboj.7600110;
RA   Lizcano J.M., Goeransson O., Toth R., Deak M., Morrice N.A.,
RA   Boudeau J., Hawley S.A., Udd L., Maekelae T.P., Hardie D.G.,
RA   Alessi D.R.;
RT   "LKB1 is a master kinase that activates 13 kinases of the AMPK
RT   subfamily, including MARK/PAR-1.";
RL   EMBO J. 23:833-843(2004).
RN   [2] {ECO:0000305, ECO:0000312|EMBL:AAF72103.1}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Zhou H.J., Huang X.W., Zhou Y., Hu S.L., Yuan J.G., Qiang B.Q.;
RT   "Cloning and isolating human MARK.";
RL   Submitted (MAY-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3] {ECO:0000305, ECO:0000312|EMBL:BAA96001.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Brain {ECO:0000269|PubMed:10819331};
RX   PubMed=10819331; DOI=10.1093/dnares/7.2.143;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVII.
RT   The complete sequences of 100 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:143-150(2000).
RN   [4] {ECO:0000305, ECO:0000312|EMBL:BAB55152.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [6] {ECO:0000305, ECO:0000312|EMBL:AAF72103.1}
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [8] {ECO:0000305}
RP   TISSUE SPECIFICITY.
RX   PubMed=9108484; DOI=10.1016/S0092-8674(00)80208-1;
RA   Drewes G., Ebneth A., Preuss U., Mandelkow E.-M., Mandelkow E.;
RT   "MARK - a novel family of protein kinases that phosphorylate
RT   microtubule-associated proteins and trigger microtubule disruption.";
RL   Cell 89:297-308(1997).
RN   [9]
RP   NEUROFIBRILLARY TANGLES IN ALZHEIMER BRAIN.
RX   PubMed=11089574; DOI=10.1093/jnen/59.11.966;
RA   Chin J.Y., Knowles R.B., Schneider A., Drewes G., Mandelkow E.M.,
RA   Hyman B.T.;
RT   "Microtubule-affinity regulating kinase (MARK) is tightly associated
RT   with neurofibrillary tangles in Alzheimer brain: a fluorescence
RT   resonance energy transfer study.";
RL   J. Neuropathol. Exp. Neurol. 59:966-971(2000).
RN   [10]
RP   FUNCTION.
RX   PubMed=11433294; DOI=10.1038/35083016;
RA   Sun T.-Q., Lu B., Feng J.-J., Reinhard C., Jan Y.N., Fantl W.J.,
RA   Williams L.T.;
RT   "PAR-1 is a Dishevelled-associated kinase and a positive regulator of
RT   Wnt signalling.";
RL   Nat. Cell Biol. 3:628-636(2001).
RN   [11]
RP   PHOSPHORYLATION AT THR-208, ENZYME REGULATION, AND FUNCTION.
RX   PubMed=17573348; DOI=10.1074/jbc.M700590200;
RA   Kojima Y., Miyoshi H., Clevers H.C., Oshima M., Aoki M., Taketo M.M.;
RT   "Suppression of tubulin polymerization by the LKB1-microtubule-
RT   associated protein/microtubule affinity-regulating kinase signaling.";
RL   J. Biol. Chem. 282:23532-23540(2007).
RN   [12]
RP   POSSIBLE INVOLVEMENT IN AUTISM.
RX   PubMed=18492799; DOI=10.1093/hmg/ddn154;
RA   Maussion G., Carayol J., Lepagnol-Bestel A.M., Tores F., Loe-Mie Y.,
RA   Milbreta U., Rousseau F., Fontaine K., Renaud J., Moalic J.M.,
RA   Philippi A., Chedotal A., Gorwood P., Ramoz N., Hager J.,
RA   Simonneau M.;
RT   "Convergent evidence identifying MAP/microtubule affinity-regulating
RT   kinase 1 (MARK1) as a susceptibility gene for autism.";
RL   Hum. Mol. Genet. 17:2541-2551(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D.,
RA   Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for
RT   efficient phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-5 AND SER-403, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-588, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [17]
RP   REVIEW.
RX   PubMed=19559622; DOI=10.1016/j.tibs.2009.03.008;
RA   Matenia D., Mandelkow E.M.;
RT   "The tau of MARK: a polarized view of the cytoskeleton.";
RL   Trends Biochem. Sci. 34:332-342(2009).
RN   [18]
RP   REVIEW.
RX   PubMed=20071654; DOI=10.1096/fj.09-148064;
RA   Marx A., Nugoor C., Panneerselvam S., Mandelkow E.;
RT   "Structure and function of polarity-inducing kinase family MARK/Par-1
RT   within the branch of AMPK/Snf1-related kinases.";
RL   FASEB J. 24:1637-1648(2010).
RN   [19]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 45-371.
RX   PubMed=16803889; DOI=10.1074/jbc.M604865200;
RA   Marx A., Nugoor C., Muller J., Panneerselvam S., Timm T., Bilang M.,
RA   Mylonas E., Svergun D.I., Mandelkow E.M., Mandelkow E.;
RT   "Structural variations in the catalytic and ubiquitin-associated
RT   domains of microtubule-associated protein/microtubule affinity
RT   regulating kinase (MARK) 1 and MARK2.";
RL   J. Biol. Chem. 281:27586-27599(2006).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 683-795, DOMAIN KA1,
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF ARG-698; ARG-701;
RP   771-ARG--LYS-773 AND 773-LYS-ARG-774.
RX   PubMed=21145462; DOI=10.1016/j.cell.2010.11.028;
RA   Moravcevic K., Mendrola J.M., Schmitz K.R., Wang Y.H., Slochower D.,
RA   Janmey P.A., Lemmon M.A.;
RT   "Kinase associated-1 domains drive MARK/PAR1 kinases to membrane
RT   targets by binding acidic phospholipids.";
RL   Cell 143:966-977(2010).
RN   [24]
RP   VARIANTS [LARGE SCALE ANALYSIS] CYS-233; THR-355; MET-530; LEU-578 AND
RP   GLY-691.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine-protein kinase involved in cell
CC       polarity and microtubule dynamics regulation. Phosphorylates DCX,
CC       MAP2, MAP4 and MAPT/TAU. Involved in cell polarity by
CC       phosphorylating the microtubule-associated proteins MAP2, MAP4 and
CC       MAPT/TAU at KXGS motifs, causing detachment from microtubules, and
CC       their disassembly. Involved in the regulation of neuronal
CC       migration through its dual activities in regulating cellular
CC       polarity and microtubule dynamics, possibly by phosphorylating and
CC       regulating DCX. Also acts as a positive regulator of the Wnt
CC       signaling pathway, probably by mediating phosphorylation of
CC       dishevelled proteins (DVL1, DVL2 and/or DVL3).
CC       {ECO:0000269|PubMed:11433294, ECO:0000269|PubMed:17573348}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC       {ECO:0000269|PubMed:14976552}.
CC   -!- CATALYTIC ACTIVITY: ATP + [tau protein] = ADP + [tau protein]
CC       phosphate.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ENZYME REGULATION: Inhibited by phosphorylation at Ser-219 (By
CC       similarity). Activated by phosphorylation on Thr-215.
CC       {ECO:0000250, ECO:0000269|PubMed:14976552,
CC       ECO:0000269|PubMed:17573348}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:21145462};
CC       Peripheral membrane protein {ECO:0000269|PubMed:21145462}.
CC       Cytoplasm, cytoskeleton {ECO:0000250}. Note=Appears to localize to
CC       an intracellular network. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9P0L2-1; Sequence=Displayed;
CC       Name=2 {ECO:0000305};
CC         IsoId=Q9P0L2-2; Sequence=VSP_051702, VSP_051704;
CC         Note=No experimental confirmation available. {ECO:0000305};
CC       Name=3 {ECO:0000305};
CC         IsoId=Q9P0L2-3; Sequence=VSP_051703, VSP_051704;
CC         Note=No experimental confirmation available. {ECO:0000305};
CC   -!- TISSUE SPECIFICITY: Highly expressed in heart, skeletal muscle,
CC       brain, fetal brain and fetal kidney. {ECO:0000269|PubMed:9108484}.
CC   -!- DOMAIN: The UBA domain does not seem to bind ubiquitin and
CC       ubiquitin-like and might play a role in regulating the enzyme
CC       conformation and localization. Activation of the kinase activity
CC       following phosphorylation at Thr-208 is accompanied by a
CC       conformational change that alters the orientation of the UBA
CC       domain with respect to the catalytic domain (By similarity).
CC       {ECO:0000250}.
CC   -!- DOMAIN: The KA1 domain mediates binding to phospholipids and
CC       targeting to membranes. Binds phosphatidic acid (PA),
CC       phosphatidylserine (PtdSer) and phosphatidylinositol 4,5-
CC       bisphosphate (PtdIns(4,5)P2). {ECO:0000269|PubMed:21145462}.
CC   -!- PTM: Phosphorylation at Thr-613 by PRKCZ/aPKC in polarized
CC       epithelial cells inhibits the kinase activity (By similarity).
CC       Phosphorylated at Thr-215 by STK11/LKB1 in complex with STE20-
CC       related adapter-alpha (STRADA) pseudo kinase and CAB39.
CC       Phosphorylation at Thr-215 by TAOK1 activates the kinase activity,
CC       leading to phosphorylation and detachment of MAPT/TAU from
CC       microtubules. Phosphorylation at Ser-219 by GSK3-beta (GSK3B)
CC       inhibits the kinase activity. {ECO:0000250,
CC       ECO:0000269|PubMed:14976552, ECO:0000269|PubMed:17573348}.
CC   -!- DISEASE: Note=Genetic variations in MARK1 may be associated with
CC       susceptibility to autism. MARK1 is overexpressed in the prefrontal
CC       cortex of patients with autism and causes changes in the function
CC       of cortical dendrites.
CC   -!- MISCELLANEOUS: Phosphorylation of MAPT/tau by MARK1 could play a
CC       role in early steps of Alzheimer disease. Pathological aggregation
CC       of MAPT/tau to neurofibrillary tangles, filamentous structures
CC       consisting of paired helical filaments (PHFs), is one of the
CC       hallmarks of Alzheimer disease. Hyperphosphorylation by MARK1
CC       could be the initial step for this abnormal aggregation of tau in
CC       Alzheimer disease and animal models of tauopathy
CC       (PubMed:11089574). {ECO:0000305|PubMed:11089574}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CAMK
CC       Ser/Thr protein kinase family. SNF1 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAA96001.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC       Sequence=BAB55152.1; Type=Frameshift; Positions=763; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF154845; AAF72103.1; -; mRNA.
DR   EMBL; AB040910; BAA96001.1; ALT_INIT; mRNA.
DR   EMBL; AK027493; BAB55152.1; ALT_FRAME; mRNA.
DR   EMBL; AL592406; CAH72462.1; -; Genomic_DNA.
DR   EMBL; AC096640; CAH72462.1; JOINED; Genomic_DNA.
DR   EMBL; AL592406; CAH72463.1; -; Genomic_DNA.
DR   EMBL; AC096640; CAH72463.1; JOINED; Genomic_DNA.
DR   EMBL; CH471100; EAW93299.1; -; Genomic_DNA.
DR   EMBL; CH471100; EAW93300.1; -; Genomic_DNA.
DR   EMBL; CH471100; EAW93302.1; -; Genomic_DNA.
DR   EMBL; BC113869; AAI13870.1; -; mRNA.
DR   EMBL; BC114478; AAI14479.1; -; mRNA.
DR   CCDS; CCDS31029.2; -. [Q9P0L2-1]
DR   CCDS; CCDS65789.1; -. [Q9P0L2-3]
DR   RefSeq; NP_001273057.1; NM_001286128.1. [Q9P0L2-3]
DR   RefSeq; NP_061120.3; NM_018650.4. [Q9P0L2-1]
DR   UniGene; Hs.497806; -.
DR   PDB; 2HAK; X-ray; 2.60 A; A/B/C/D/E/F/G/H=45-371.
DR   PDB; 3OSE; X-ray; 1.70 A; A=683-795.
DR   PDBsum; 2HAK; -.
DR   PDBsum; 3OSE; -.
DR   ProteinModelPortal; Q9P0L2; -.
DR   SMR; Q9P0L2; -.
DR   BioGrid; 110309; 16.
DR   DIP; DIP-39777N; -.
DR   IntAct; Q9P0L2; 13.
DR   MINT; MINT-3975018; -.
DR   STRING; 9606.ENSP00000355884; -.
DR   BindingDB; Q9P0L2; -.
DR   ChEMBL; CHEMBL5940; -.
DR   GuidetoPHARMACOLOGY; 2097; -.
DR   iPTMnet; Q9P0L2; -.
DR   PhosphoSitePlus; Q9P0L2; -.
DR   BioMuta; MARK1; -.
DR   DMDM; 124056494; -.
DR   EPD; Q9P0L2; -.
DR   MaxQB; Q9P0L2; -.
DR   PaxDb; Q9P0L2; -.
DR   PeptideAtlas; Q9P0L2; -.
DR   PRIDE; Q9P0L2; -.
DR   DNASU; 4139; -.
DR   Ensembl; ENST00000366917; ENSP00000355884; ENSG00000116141. [Q9P0L2-1]
DR   Ensembl; ENST00000366918; ENSP00000355885; ENSG00000116141. [Q9P0L2-3]
DR   GeneID; 4139; -.
DR   KEGG; hsa:4139; -.
DR   UCSC; uc001hmm.6; human. [Q9P0L2-1]
DR   CTD; 4139; -.
DR   DisGeNET; 4139; -.
DR   GeneCards; MARK1; -.
DR   HGNC; HGNC:6896; MARK1.
DR   HPA; HPA007421; -.
DR   HPA; HPA008061; -.
DR   MIM; 606511; gene.
DR   neXtProt; NX_Q9P0L2; -.
DR   OpenTargets; ENSG00000116141; -.
DR   PharmGKB; PA30639; -.
DR   eggNOG; KOG0586; Eukaryota.
DR   eggNOG; ENOG410XNQ0; LUCA.
DR   GeneTree; ENSGT00790000122947; -.
DR   HOVERGEN; HBG052453; -.
DR   InParanoid; Q9P0L2; -.
DR   KO; K08798; -.
DR   PhylomeDB; Q9P0L2; -.
DR   TreeFam; TF315213; -.
DR   SignaLink; Q9P0L2; -.
DR   SIGNOR; Q9P0L2; -.
DR   ChiTaRS; MARK1; human.
DR   EvolutionaryTrace; Q9P0L2; -.
DR   GeneWiki; MARK1; -.
DR   GenomeRNAi; 4139; -.
DR   PRO; PR:Q9P0L2; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000116141; -.
DR   CleanEx; HS_MARK1; -.
DR   ExpressionAtlas; Q9P0L2; baseline and differential.
DR   Genevisible; Q9P0L2; HS.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; ISS:UniProtKB.
DR   GO; GO:0015630; C:microtubule cytoskeleton; TAS:ProtInc.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0070300; F:phosphatidic acid binding; IDA:UniProtKB.
DR   GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; IDA:UniProtKB.
DR   GO; GO:0001786; F:phosphatidylserine binding; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:UniProtKB.
DR   GO; GO:0050321; F:tau-protein kinase activity; ISS:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; ISS:UniProtKB.
DR   GO; GO:0030010; P:establishment of cell polarity; IEA:InterPro.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:UniProtKB.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IEA:InterPro.
DR   GO; GO:0001764; P:neuron migration; ISS:UniProtKB.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0016055; P:Wnt signaling pathway; IEA:UniProtKB-KW.
DR   InterPro; IPR028375; KA1/Ssp2_C.
DR   InterPro; IPR001772; KA1_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR033624; MARK/par1.
DR   InterPro; IPR033627; MARK1.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   InterPro; IPR015940; UBA.
DR   PANTHER; PTHR24346; PTHR24346; 1.
DR   PANTHER; PTHR24346:SF36; PTHR24346:SF36; 1.
DR   Pfam; PF02149; KA1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00627; UBA; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SMART; SM00165; UBA; 1.
DR   SUPFAM; SSF103243; SSF103243; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50032; KA1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS50030; UBA; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Autism;
KW   Autism spectrum disorder; Cell membrane; Complete proteome; Cytoplasm;
KW   Cytoskeleton; Kinase; Lipid-binding; Magnesium; Membrane;
KW   Metal-binding; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase;
KW   Wnt signaling pathway.
FT   CHAIN         1    795       Serine/threonine-protein kinase MARK1.
FT                                /FTId=PRO_0000086298.
FT   DOMAIN       60    311       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      325    370       UBA. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00212}.
FT   DOMAIN      746    795       KA1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00565}.
FT   NP_BIND      66     74       ATP. {ECO:0000250|UniProtKB:Q9H0K1,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   ACT_SITE    182    182       Proton acceptor.
FT                                {ECO:0000250|UniProtKB:Q9H0K1,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159,
FT                                ECO:0000255|PROSITE-ProRule:PRU10027}.
FT   BINDING      89     89       ATP. {ECO:0000250|UniProtKB:O08678,
FT                                ECO:0000255|PROSITE-ProRule:PRU00159}.
FT   MOD_RES       5      5       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     208    208       Phosphothreonine.
FT                                {ECO:0000269|PubMed:17573348}.
FT   MOD_RES     215    215       Phosphothreonine; by LKB1 and TAOK1.
FT                                {ECO:0000269|PubMed:14976552}.
FT   MOD_RES     219    219       Phosphoserine; by GSK3-beta.
FT                                {ECO:0000250|UniProtKB:O08678}.
FT   MOD_RES     382    382       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VHJ5}.
FT   MOD_RES     390    390       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VHJ5}.
FT   MOD_RES     393    393       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VHJ5}.
FT   MOD_RES     403    403       Phosphoserine.
FT                                {ECO:0000244|PubMed:18691976}.
FT   MOD_RES     423    423       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VHJ5}.
FT   MOD_RES     444    444       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O08678}.
FT   MOD_RES     475    475       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VHJ5}.
FT   MOD_RES     588    588       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648}.
FT   MOD_RES     613    613       Phosphothreonine; by PKC/PRKCZ.
FT                                {ECO:0000250}.
FT   MOD_RES     666    666       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q8VHJ5}.
FT   VAR_SEQ       1    135       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_051702.
FT   VAR_SEQ     120    141       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:10819331}.
FT                                /FTId=VSP_051703.
FT   VAR_SEQ     663    677       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:10819331,
FT                                ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_051704.
FT   VARIANT     233    233       Y -> C (in a gastric adenocarcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040760.
FT   VARIANT     355    355       N -> T (in an ovarian serous carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040761.
FT   VARIANT     530    530       V -> M (in dbSNP:rs56212551).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040762.
FT   VARIANT     578    578       P -> L (in dbSNP:rs55691439).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040763.
FT   VARIANT     645    645       R -> G (in dbSNP:rs12123778).
FT                                /FTId=VAR_030018.
FT   VARIANT     691    691       E -> G (in dbSNP:rs55688276).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040764.
FT   MUTAGEN     215    215       T->A: Prevents phosphorylation and
FT                                activation by STK11/LKB1 complex.
FT                                {ECO:0000269|PubMed:14976552}.
FT   MUTAGEN     215    215       T->E: Constitutively active.
FT                                {ECO:0000269|PubMed:14976552}.
FT   MUTAGEN     698    698       R->S: Impairs phospholipid-binding,
FT                                targeting to membrane and vesicle-
FT                                binding; when associated with S-701.
FT                                {ECO:0000269|PubMed:21145462}.
FT   MUTAGEN     701    701       R->S: Impairs phospholipid-binding,
FT                                targeting to membrane and vesicle-
FT                                binding; when associated with S-698.
FT                                {ECO:0000269|PubMed:21145462}.
FT   MUTAGEN     771    773       RFK->AFA: Impairs phospholipid-binding.
FT                                {ECO:0000269|PubMed:21145462}.
FT   CONFLICT     16     16       E -> V (in Ref. 2; AAF72103).
FT                                {ECO:0000305}.
FT   CONFLICT     20     20       S -> T (in Ref. 2; AAF72103).
FT                                {ECO:0000305}.
FT   CONFLICT    522    522       D -> N (in Ref. 4; BAB55152).
FT                                {ECO:0000305}.
FT   CONFLICT    544    544       V -> A (in Ref. 4; BAB55152).
FT                                {ECO:0000305}.
FT   CONFLICT    763    763       P -> A (in Ref. 4; BAB55152).
FT                                {ECO:0000305}.
FT   CONFLICT    794    794       K -> M (in Ref. 3; BAA96001).
FT                                {ECO:0000305}.
FT   STRAND       60     68       {ECO:0000244|PDB:2HAK}.
FT   STRAND       70     79       {ECO:0000244|PDB:2HAK}.
FT   TURN         80     82       {ECO:0000244|PDB:2HAK}.
FT   STRAND       85     92       {ECO:0000244|PDB:2HAK}.
FT   HELIX        98    113       {ECO:0000244|PDB:2HAK}.
FT   STRAND      122    127       {ECO:0000244|PDB:2HAK}.
FT   STRAND      129    136       {ECO:0000244|PDB:2HAK}.
FT   HELIX       144    151       {ECO:0000244|PDB:2HAK}.
FT   HELIX       156    176       {ECO:0000244|PDB:2HAK}.
FT   HELIX       185    187       {ECO:0000244|PDB:2HAK}.
FT   STRAND      188    190       {ECO:0000244|PDB:2HAK}.
FT   STRAND      196    198       {ECO:0000244|PDB:2HAK}.
FT   STRAND      221    223       {ECO:0000244|PDB:2HAK}.
FT   HELIX       225    229       {ECO:0000244|PDB:2HAK}.
FT   HELIX       236    252       {ECO:0000244|PDB:2HAK}.
FT   HELIX       262    271       {ECO:0000244|PDB:2HAK}.
FT   HELIX       282    291       {ECO:0000244|PDB:2HAK}.
FT   HELIX       296    298       {ECO:0000244|PDB:2HAK}.
FT   HELIX       302    306       {ECO:0000244|PDB:2HAK}.
FT   HELIX       309    312       {ECO:0000244|PDB:2HAK}.
FT   STRAND      316    318       {ECO:0000244|PDB:2HAK}.
FT   HELIX       333    342       {ECO:0000244|PDB:2HAK}.
FT   HELIX       346    354       {ECO:0000244|PDB:2HAK}.
FT   HELIX       360    367       {ECO:0000244|PDB:2HAK}.
FT   HELIX       714    727       {ECO:0000244|PDB:3OSE}.
FT   STRAND      731    736       {ECO:0000244|PDB:3OSE}.
FT   STRAND      739    745       {ECO:0000244|PDB:3OSE}.
FT   TURN        747    750       {ECO:0000244|PDB:3OSE}.
FT   STRAND      753    762       {ECO:0000244|PDB:3OSE}.
FT   HELIX       763    765       {ECO:0000244|PDB:3OSE}.
FT   STRAND      767    777       {ECO:0000244|PDB:3OSE}.
FT   HELIX       779    792       {ECO:0000244|PDB:3OSE}.
SQ   SEQUENCE   795 AA;  89003 MW;  71BF6EB76912631B CRC64;
     MSARTPLPTV NERDTENHTS VDGYTEPHIQ PTKSSSRQNI PRCRNSITSA TDEQPHIGNY
     RLQKTIGKGN FAKVKLARHV LTGREVAVKI IDKTQLNPTS LQKLFREVRI MKILNHPNIV
     KLFEVIETEK TLYLVMEYAS GGEVFDYLVA HGRMKEKEAR AKFRQIVSAV QYCHQKYIVH
     RDLKAENLLL DGDMNIKIAD FGFSNEFTVG NKLDTFCGSP PYAAPELFQG KKYDGPEVDV
     WSLGVILYTL VSGSLPFDGQ NLKELRERVL RGKYRIPFYM STDCENLLKK LLVLNPIKRG
     SLEQIMKDRW MNVGHEEEEL KPYTEPDPDF NDTKRIDIMV TMGFARDEIN DALINQKYDE
     VMATYILLGR KPPEFEGGES LSSGNLCQRS RPSSDLNNST LQSPAHLKVQ RSISANQKQR
     RFSDHAGPSI PPAVSYTKRP QANSVESEQK EEWDKDVARK LGSTTVGSKS EMTASPLVGP
     ERKKSSTIPS NNVYSGGSMA RRNTYVCERT TDRYVALQNG KDSSLTEMSV SSISSAGSSV
     ASAVPSARPR HQKSMSTSGH PIKVTLPTIK DGSEAYRPGT TQRVPAASPS AHSISTATPD
     RTRFPRGSSS RSTFHGEQLR ERRSVAYNGP PASPSHETGA FAHARRGTST GIISKITSKF
     VRRDPSEGEA SGRTDTSRST SGEPKERDKE EGKDSKPRSL RFTWSMKTTS SMDPNDMMRE
     IRKVLDANNC DYEQKERFLL FCVHGDARQD SLVQWEMEVC KLPRLSLNGV RFKRISGTSI
     AFKNIASKIA NELKL
//
